ir.tgtherapeutics.comInvestor Relations | TG Therapeutics, Inc.
ir.tgtherapeutics.com Profile
Ir.tgtherapeutics.com is a subdomain of tgtherapeutics.com, which was created on 2011-12-06,making it 12 years ago.
Description：The Investor Relations website contains information about TG Therapeutics, Inc.'s business for stockholders, potential investors, and financial...
Discover ir.tgtherapeutics.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.tgtherapeutics.com Information
| HomePage size: 54.516 KB |
| Page Load Time: 0.076418 Seconds |
| Website IP Address: 172.231.14.194 |
ir.tgtherapeutics.com Similar Website
| Masonite International Corp. - Investor Relations - Investor Relations |
| Block, Inc. (SQ) Investor Relations - Investor Relations |
| Gen Investor Relations - Investor Relations |
| MindChamps PreSchool Limited - Investor Relations: Investor Relations |
| Home - Ayala Land Investor Relations : Ayala Land Investor Relations |
| Universal Technical Institute's Investor Relations - UTI Investor Relations |
| Ameriprise Financial Investor Relations | Investor Relations |
| Meridian Bank Investor Relations - Meridian Bank Investor Relations |
| Armstrong World Industries Investor Relations | Armstrong Flooring Investor Relations |
| Walmart Investor Relations - Investor Relations |
| Alphabet Investor Relations - Investor Relations - Alphabet |
| Investor Relations | Jacobs - Investor Relations |
ir.tgtherapeutics.com PopUrls
| TG Therapeutics, Inc.: Investor Relations https://ir.tgtherapeutics.com/ |
| Press Releases https://ir.tgtherapeutics.com/press-releases |
| Stock Information https://ir.tgtherapeutics.com/stock-information |
| Events https://ir.tgtherapeutics.com/events |
| 0001558370-21-014445 | 8-K | XBRL Viewer https://ir.tgtherapeutics.com/node/16916/xbrl-viewer |
| 0001558370-21-009752 | 8-K | XBRL Viewer https://ir.tgtherapeutics.com/node/16591/xbrl-viewer |
| 0001558370-21-008523 | 8-K | XBRL Viewer https://ir.tgtherapeutics.com/node/16531/xbrl-viewer |
| FAQs https://ir.tgtherapeutics.com/investor-faqs |
| Investor & Media Relations Contact https://ir.tgtherapeutics.com/contact-us |
| Quarterly Results | TG Therapeutics, Inc. https://ir.tgtherapeutics.com/financial-information/quarterly-results |
| Annual Reports | TG Therapeutics, Inc. https://ir.tgtherapeutics.com/financial-information/annual-reports |
| TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 ... https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-provides-preliminary-fourth-quarter-and-full |
| TG Therapeutics Provides Business Update and Reports First Quarter 2024 ... https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-provides-business-update-and-reports-first-3 |
| TG Therapeutics Announces Global License Agreement with Precision ... https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-global-license-agreement-precision |
| TG Therapeutics Provides Business Update and Reports Second Quarter ... https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-provides-business-update-and-reports-second-3 |
ir.tgtherapeutics.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1589754523" |
| Expect-CT: max-age=0, report-uri="/report-expect-ct-violation" |
| Feature-Policy: "accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;sync-xhr self;usb none;vibrate none;vr none", From-Origin: same |
| Last-Modified: Sun, 17 May 2020 22:28:43 GMT |
| Link: http://ir.tgtherapeutics.com/; rel="shortlink", http://ir.tgtherapeutics.com/; rel="canonical", http://ir.tgtherapeutics.com/investor-relations; rel="alternate"; hreflang="en", http://ir.tgtherapeutics.com/investor-relations; rel="revision" |
| Referrer-Policy: no-referrer-when-downgrade |
| Server: nginx |
| X-Age: 0 |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Generator: Drupal 8 (https://www.drupal.org) |
| X-Request-ID: v-c3fc25a8-988d-11ea-9974-cf046180a01e |
| X-UA-Compatible: IE=edge |
| X-XSS-Protection: 1; mode=block |
| Content-Length: 11835 |
| X-EdgeConnect-MidMile-RTT: 107, 107 |
| X-EdgeConnect-Origin-MEX-Latency: 763, 763 |
| Cache-Control: public, max-age=0, s-maxage=1800 |
| Expires: Sun, 17 May 2020 22:28:44 GMT |
| Date: Sun, 17 May 2020 22:28:44 GMT |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: SimpleSAMLSessionID=30c4df2938f8cc6008c7c315586fc721; path=/; secure; HttpOnly, DrupalVisitorMobile=0; path=/; Secure; HttpOnly |
ir.tgtherapeutics.com Meta Info
| charset="utf-8"/ |
| content="Investor Relations | TG Therapeutics, Inc." name="title"/ |
| content="TG Therapeutics, Inc." property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="The Investor Relations website contains information about TG Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts." name="description"/ |
| content="http://ir.tgtherapeutics.com/investor-relations" property="og:url"/ |
| content="Investor Relations | TG Therapeutics, Inc." property="og:title"/ |
| content="no-referrer" name="referrer"/ |
| content="The Investor Relations website contains information about TG Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts." property="og:description"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
ir.tgtherapeutics.com Ip Information
| Ip Country: United States |
| Latitude: 37.751 |
| Longitude: -97.822 |
ir.tgtherapeutics.com Html To Plain Text
Our Story Message From CEO Our Leadership Our Board Our Science Our Approach Therapeutic Focus Work with Us Our Pipeline Overview UBLITUXIMAB UMBRALISIB TG-1501 TG-1701 TG-1801 Our Publications Our Trials Overview Pivotal Trials Investors & Media Press Releases Stock Information Historic Stock Lookup SEC Filings & Financials Quarterly Results Annual Reports SEC Filings Events IR & Media Contact Management Team Corporate Governance FAQs CAREERS CONTACT US Twitter CloseOur Story Message From CEO Our Leadership Our Board Our Science Our Approach Therapeutic Focus Work with Us Our Pipeline Overview UBLITUXIMAB UMBRALISIB TG-1501 TG-1701 TG-1801 Our Publications Our Trials Overview Pivotal Trials Investors & Media Press Releases Stock Information Historic Stock Lookup SEC Filings & Financials Quarterly Results Annual Reports SEC Filings Events IR & Media Contact Management Team Corporate Governance FAQs Investors & Media Investor Relations Investor Relations TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an oral, once-daily inhibitor of PI3K-delta. Umbralisib uniquely inhibits CK1-epsilon, which may allow it to overcome certain tolerability issues associated with first generation PI3K-delta inhibitors. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody, TG-1501, its covalently-bound Bruton’s Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801, into Phase 1 development. TG Therapeutics is headquartered in New York City. Currently, TG Therapeutics uses the following social media channels: - Twitter November 2019 Corporate Presentation Quote Chart NASDAQ: TGTX Change Volume 52 Week High 52 Week Low May 17, 2020 6:28 PM EDT Copyright West LLC. Minimum 15 minutes delayed. Recent Releases May 15, 2020 TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Meeting May 14, 2020 TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock View all Email Alerts RSS News Feeds Print Page Share facebook linkedin twitter Search 2 Gansevoort Street, 9th Floor New York, NY 10014 Email Us (212) 554-4484 TG Therapeutics © . All rights reserved. Join us Contact Us Privacy Policy Terms of...
ir.tgtherapeutics.com Whois
Domain Name: TGTHERAPEUTICS.COM Registry Domain ID: 1690715074_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2023-12-07T17:17:57Z Creation Date: 2011-12-06T14:57:45Z Registry Expiry Date: 2024-12-06T14:57:45Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: KARL.NS.CLOUDFLARE.COM Name Server: ROSEMARY.NS.CLOUDFLARE.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T20:11:10Z <<<